Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:11 PM
Ignite Modification Date:
2025-12-24 @ 9:11 PM
NCT ID:
NCT00546104
Eligibility Criteria:
Inclusion Criteria:
* Measurable Stage IV or inoperable Stage III advanced breast cancer.
* There is no limit on the number of prior therapies.
* At least 3 weeks since prior chemotherapy, biological or hormonal therapy.
* At least 2 weeks since surgical biopsy.
* At least 3 weeks since major (open thoracic/abdominal/cardiac) surgery.
* No central nervous system (CNS) metastases except solitary brain metastasis
* No cardiac dysfunction
* left ventricular ejection fraction (LVEF) ≥ 50% as determined by multiple gated acquisition scan (MUGA)/echocardiogram
* Adequate blood counts
* Normal liver and kidney function
* Negative serum pregnancy test.
* Able to provide informed consent
Exclusion Criteria:
* Pregnant or breast feeding.
* Prior treatment with dasatinib.
* Bone as the only site of disease.
* Significant gastrointestinal bleeding
* Septicemia, infection, acute hepatitis, hypokalemia, or hypomagnesemia
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Study:
NCT00546104
Study Brief:
Protocol Section:
NCT00546104